DOI: 10.1055/s-00000030

Der Klinikarzt

References

Loibl S, O‘Shaughnessy J, Untch M. et al.
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.

Lancet Oncol 2018;
19: 497-509

Download Bibliographical Data

Search in:
Access:
Access: